Terms of Use
These Terms of Use outline the use of information contained on the Azura website (“Site”) by website users (each, a “User”).

This website and its content are subject to copyright under the laws of Australia and other countries. Unless otherwise indicated, copyright in this website and its content is owned by Azura Ophthalmics Pty Ltd (“Azura”). In addition, third parties may own the copyright in some materials incorporated within this website.

Users must not modify any content nor remove the copyright notice from any content on this website. Other than as permitted under the Copyright Act 1968 (Cth), no material on this website may be reproduced without the prior written permission of Azura.


While every effort has been made to ensure the quality and currency of the information available on this Site, Azura cannot guarantee and assumes no legal liability or responsibility for the accuracy, currency, completeness or interpretation of the information.

Azura does not provide the information contained on this Site by way of professional advice on a particular matter. This Site is not a substitute for independent professional advice and is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes. Azura does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this Site.

These Terms of Use were last updated on September 8, 2022.

Privacy Policy
Purpose and scope

This policy outlines how Azura Ophthalmics Pty Ltd (“Azura”) collects, uses, maintains and discloses Personal Information collected from users (each, a “User”) of the Azura website (“Site”).

Collection of Personal Information

“Personal Information” is information that can be used to identify an individual. Azura collects Personal Information from Users when Users visit the Site and choose to fill out a contact request form. If Users choose to complete a contact request form they will be asked to provide their name, email address and phone number.

Web browser cookies

The Site may use “cookies” to enhance User experience using analytics and for security purposes. Cookies do not contain any Personal Information and Azura does not use cookies to collect any Personal Information about Users. The User’s web browser stores cookies on the User’s device to support these analytic and security tasks. Users may choose to set their web browser to refuse cookies, or to alert them when cookies are being sent. If Users do so, please note that some parts of the Site may not function properly.

Use of collected Personal Information

Azura’s sole purpose for collecting User’s Personal Information is to respond to Users’ enquiries, questions and/or other requests via the email addresses and phone numbers that they have provided.

Protection of Personal Information

Azura adopts appropriate storage and processing practices and security measures to protect User’s Personal Information against unauthorized access, alteration, or disclosure.

Sharing Personal Information

Azura does not disclose User’s Personal Information to any third parties.

Third party websites

Users may find content on the Site that links to the sites of company partners and other third parties. Azura does not control the content of these linked websites and disclaims any responsibility for the practices employed by websites linked to the Site. Browsing and interaction on any linked website is subject to that website’s terms and policies.

Changes to this privacy policy

Azura may update this privacy policy from time to time. When this occurs, the version and date will be updated and displayed at the bottom of this page.

Contact us

If you have any questions about this Privacy Policy, would like to make a complaint, or would like to request access to any Personal Information that Azura holds about you, please contact Azura at info@azuraophthalmics.com.

This Privacy Policy was last updated on September 8, 2022.

  1. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on Meibomian gland dysfunction: executive summary. Inv Oph & Vis Sci. 2011;52(4):1922-1929.​
  2. ​Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pthophysiology of the meibomian glands. Investigative Ophthalmology and Visual Science. 2011;52(4):1938-78.​
  3. ​Nichols JJ, Willcox MDP, Bron AJ, et al. The TFOS International Workshop on Contact Lens Discomfort: Executive Summary. Invest Ophthalmol Vis Sci. 2013;54:TFOS7–TFOS13.​
  4. ​Bodemer AA. Keratolytic Agent. From: Integrative Medicine (Fourth Edition), 2018; Pages 726-738. ​
  5. ​Bahn GC. The treatment of seborrheic blepharitis. South Med J. 1954 Aug;47(8):749-53.​
  6. ​Cohen LB. Use of selsun in blepharitis marginalis. Am J Ophthalmol. 1954-1955 Oct;38(4):560-2.​​
  7. ​Wong AS, Fasanaella RM, Haley LD, Marshall CL, Krehl WA. Selenium (selsun) in the treatment of marginal blepharitis. AMA Arch Ophthalmol. 1956 Feb;55(2):246-53.​
  8. ​Thygeson P, Vaughan DG Jr. Seborrheic blepharitis. Trans Am Ophthalmol Soc. 1954-1955;52:173-88.​ ​
  9. ​Smith EW and Maibach HI. Percutaneous penetration enhancers. 1995; CRC press LLC.​
  10. ​Debevec-McKenney E, Syrnioti A, Mauldin A, Lee JH. 2022. Keratolytics: Nursing Pharmacology. Osmosis from Elsevier.​
  11. ​Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian glands. Investigative Ophthalmology and Visual Science. 2011;52(4):1938-1978.​
  12. ​Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on Meibomian gland dysfunction: executive summary. Inv Oph & Vis Sci. 2011;52(4):1922-1929​.
  13. ​Nichols JJ, Willcox MDP, Bron AJ, et al. The TFOS International Workshop on Contact Lens Discomfort: Executive Summary. Invest Ophthalmol Vis Sci. 2013;54:TFOS7–TFOS13.​
  14. ​Bron AJ et al. The TFOS DEWS: Introduction. TFOS DEWS II pathophysiology report. The Ocular Surface. 2017:15:438-510.​
  15. ​Knop E, et al. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1938-78.
  16. ​Yoo SE, et al. Korean J Ophthalmol. 2005 Dec;19(4):258-633.​​
  17. ​Alster Y, et al. Invest Ophthalmol Vis Sci. 2021 June 62:693.
  18. ​Azura Ophthalmics, data on file: Study AZR100PC03.
  19. ​​​ ​Efron N, Jones L, Bron AJ, et al. The TFOS International Workshop on Contact Lens Discomfort: Report of the Contact Lens Interactions With the Ocular Surface and Adnexa Subcommittee. Invest Ophthalmol Vis Sci. 2013;54:TFOS98–TFOS122.​
  20. ​Solomon A. Allergic manifestations of contact lens wearing. Curr Opin Allergy Clin Immunol. 2016;16(5):492-7.​
  21. ​Blackie CA, Korb DR, Knop E, Bedi R, Knop N, Holland EJ. Nonobvious obstructive meibomian gland dysfunction. Cornea. 2010;29(12):1333-45.​
  22. ​Foulks GN, Bran AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;107-126.
  23. Horm MM. Use of cyclosporine 0.05% ophthalmic solution for contact lens-intolerant patients. Eye Contact Lens. 2006;32(2):109-11.
Scroll to Top